Fatemeh Erfanifar

Dr, Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Publications

• Research   
  The Evaluation of Atypical Antipsychotic Augmentation with Atomoxetine in the Reduction of Negative Symptoms in Patients with Schizophrenia: A Randomized, DoubleBlind, Placebo-Controlled Clinical Trial
  Author(s): Maryam Pourshams, Forough Riahi, Ashraf Tashakori and Fatemeh Erfanifar*
  
  Background and purpose: Schizophrenia is one of the most severe psychiatric disorders with a chronic and debilitating condition. Negative symptoms are common in patients with schizophrenia that have not yet responded well to drugs. The aim of this study is to evaluate the effect of adding Atomoxetine to atypical antipsychotics in reducing the negative symptoms in schizophrenic patients. Materials and methods: In this randomized, double-blind, placebo-controlled clinical trial during 2018-2020, 60 DSM-V based schizophrenic patients were enrolled to the study. They were divided into case (n=30) and control (n=30) groups. Case group received Atomoxetine, 40 mg daily in the first week and 40 mg daily in the following weeks and the control group received placebo. The effect of medication on negative symptoms in both groups was compared .. Read More»
  

  Abstract PDF